/PRNewswire/ GlycoEra AG, a pioneering company advancing a pipeline of extracellular protein degraders for the treatment of autoimmune disorders, today.
Financing round co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners with participation from LimmaTech Biologics AG GlycoEra AG announced today the close of a CHF 45 million ($49 million)